AUTHORS
Laura Teresa Morton, PhD, Laurence King2, Supreet Bola Kaur3, Maciej Szukszto4, Charlotte Boulton5, felix O'Farrell6, Hugh O'brein, PhD7, Sergio Quezada, PhD8, Marc R. Mansour, MD, PhD, FRCPath, MRCP9
AFFILIATIONS
1 University college London, London, United Kingdom
2 University college London, London, United Kingdom
3 University college London, London, United Kingdom
4 University college London, London, United Kingdom
5 University college London, London, United Kingdom
6 University college London, London, United Kingdom
7 Achilles Therapeutics, London, United Kingdom
8 University college London, London, United Kingdom
9 University college London, London, United Kingdom
ABSTRACT
T-cell receptor (TCR) based cellular-therapies are emerging as a promising treatment option against haematological and solid malignancies. These therapies rely upon TCR recognition of immunogenic epitopes presented in HLA-molecules on the surface of tumour cells, resulting in T-cell release of granzyme B and activation of pro-apoptotic pathways leading to tumour cell death. Therapeutic success is dependent on the computational prediction of immunogenic tumour antigens and currently only 2-3% of predicted antigens elicit a functional T-cell response. Identification of immunogenic T-cell epitopes remains a challenge and is laborious due to the scale of the immunopeptidome landscape, highlighting the need for standardized, scalable platforms to accelerate therapeutic target discovery.
Here, we designed a novel Cleavage enabled Reporter (CleavER) to identify immunogenic T-cell epitopes in a high-throughput approach. CleavER links a protein-degradation tag mFKBP12, via a granzyme-B cleavage sequence to a fluorescent reporter protein and dTAG-13 treatment permits degradation of the CleavER reporter. Upon T-cell recognition of CleavER cells, granzyme-B cleaves the fluorescent reporter protein from the mFKBP12 tag and treatment with dTAG-13 results in recognised CleavER cells remaining reporter protein positive. For antigen screening, we lentivirally expressed antigenic DNA libraries, in mono-allelic CleavER cells, including positive controls derived from well characterised T-cell responses against CMV:NLV and NYESO:SLL epitopes restricted to HLA-A2. To determine if CleavER would function as an antigenic reporter, co-cultures with antigen-specific T-cells were conducted.
We demonstrated after co-culture with CMV-specific T-cells, mono-allelic HLA-A2+ CleavER cells expressing CMV:NLV remained reporter protein positive following treatment with dTAG-13. CleavER signal was dependent on both the frequency of Ag-specific T-cells and antigen bearing cells and CleavER sensitivity was shown to detect antigen as low as 1%. Furthermore, next generation sequencing revealed CMV:NLV was the only epitope enriched in reporter protein positive cells compared to reporter protein negative CleavER cells expressing an antigen library encoding 20,000 neoantigens, identifying CMV:NLV as an immunogenic T-cell epitope. Finally, CleavER signal improved 4-fold after knocking out SerpinB9, a granzyme B inhibitor, demonstrating the dependence on CleavER activity on Granzyme B cleavage.
In conclusion, CleavER is a scalable, high throughput platform which enables identification of specific functional immunogenic T-cell epitopes from complex antigen libraries. This approach has the potential to accelerate the identification of therapeutic epitopes for TCR-based cellular therapies.
DISCLOSURES
Laura Teresa Morton, PhD: No relevant conflicts of interest to declare.